Japer Therapeutics Warrants
JSPRW
5 hedge funds and large institutions have $129K invested in Japer Therapeutics Warrants in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
0.11% less ownership
Funds ownership: 6.18% → 6.07% (-0.11%)
33% less capital invested
Capital invested by funds: $193K → $129K (-$64.1K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$2.15K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$200 |
| 3 |
Walleye Trading
New York
|
-$157 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Walleye Capital
New York
| $80.1K | -$2.15K | -13,579 | -2% |
|
|
TCM
2
Tenor Capital Management
New York
| $35.8K | – | – | – |
|
|
ZA
3
Zazove Associates
Incline Village,
Nevada
| $7.74K | – | – | – |
|
|
4
Walleye Trading
New York
| $4.88K | -$157 | -996 | -3% |
|
5
JP Morgan Chase
New York
| $420 | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $133 | -$200 | -1,268 | -49% |
|
JSPRW Hedge Fund Activity: Q1 2025 in Review
5 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Japer Therapeutics Warrants (JSPRW) for Q1 2025, worth a combined $129K — down 33% from $193K a quarter earlier.
Fund positioning in JSPRW was balanced in Q1 2025: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 3 trimmed.
The largest seller was Walleye Capital, cutting an estimated $2.15K.
- 5 institutional investors held Japer Therapeutics Warrants (JSPRW) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $129K of Japer Therapeutics Warrants stock for Q1 2025, down 33% quarter-over-quarter.
- 0 funds opened new Japer Therapeutics Warrants positions in Q1 2025 and 0 closed out.
- The largest Japer Therapeutics Warrants seller in Q1 2025 was Walleye Capital, an estimated $2.15K sold.
Based on aggregated 13F filings for Q1 2025.